Health Care Up on Novo Nordisk Optimism -- Health Care Roundup
Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...
S&P 500 rises, Nasdaq jumps 2% in recovery rally after Nvidia-led sell-off: Live updates
The Nasdaq Composite slid more than 3% in Monday’s trading as a slate of AI-related plays, including chip darling Nvidia, ...
News Highlights: Top Global Markets News of the Day - Wednesday at 9 AM ET
Europe 'Must Fix' Weaknesses to Compete, EU's Von der Leyen Says EU nations must work together quickly to help the bloc compete against global economic powerhouses like China and the U.S., European ...
Investopedia2d
Dow Jones Today: Stocks Tumble on Concerns About China's AI Advances; Chipmakers and Nuclear Power Shares Plunge
He has more than two decades of experience as a journalist and newsroom leader, including 25 years at Dow Jones and The Wall ... Wegovy and Eli Lilly's (LLY) Zepbound, had even better outcomes ...
10 Stock and Bond Market Insights That Are Hardly ‘Dull’
Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...
Wall Street Journal6d
Stocks to Watch Friday: Novo Nordisk, Eli Lilly, Amex, Verizon
Novo's U.S. and Europe-listed stocks leapt. Shares of rival Eli Lilly (LLY) also rallied. 🔎 Affirm (AFRM): The "buy-now-pay-later" lender secured $750 million in funding from insurer Liberty ...
Zacks.com on MSN1d
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Eli Lilly price target lowered to $1,190 from $1,250 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Yahoo Finance4d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Business Insider3d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...